Literature DB >> 20146733

Upper gastrointestinal endoscopic findings in the era of highly active antiretroviral therapy.

M Nkuize1, S De Wit, V Muls, M Arvanitakis, M Buset.   

Abstract

BACKGROUND: The current literature suggests that there has been a decrease in opportunistic diseases among HIV-infected patients since the widespread introduction of highly active antiretroviral therapy (HAART) in 1995.
OBJECTIVES: The aim of the study was to investigate the impact of HAART and CD4 lymphocyte count on diseases of the upper gastrointestinal (UGI) tract, digestive symptoms, and endoscopic and histological observations.
METHODS: A review of 706 HIV-infected patients who underwent GI endoscopy was undertaken. The cohort was divided into three groups: group 1 (G1), pre-HAART, consisting of 239 patients who underwent endoscopy between January 1991 and December 1994; group 2 (G2), early HAART, consisting of 238 patients who underwent endoscopy between January 1999 and December 2002; and group 3 (G3), recent HAART, consisting of 229 patients who underwent endoscopy between January 2005 and December 2008. Parameters studied included age, gender, opportunistic chemoprophylaxis, antiretroviral therapies, CD4 cell counts, symptoms, observations at the first UGI endoscopy and histology.
RESULTS: When G1, G2 and G3 were compared, significant increases were seen over time in the following parameters: the percentage of women, the mean CD4 cell count, and the frequencies of reflux symptoms, gastroesophageal reflux disease (GERD), inflammatory gastropathy, gastric ulcer and Helicobacter pylori (HP) infection. Significant decreases were seen in the frequencies of the administration of anti-opportunistic infection prophylaxis, odynophagia/dysphagia, acute/chronic diarrhoea, candida oesophagitis, nonspecific oesophageal ulcer and Kaposi sarcoma. No significant change was observed in the other parameters, i.e. digestive bleeding, duodenal ulcer and inflammatory duodenopathy.
CONCLUSION: These results suggest a correlation between the improvement of immunity as a result of more efficient antiviral therapy and the decrease in the frequency of digestive diseases in AIDS, mainly opportunistic pathologies. However, HP infection, reflux symptoms and GERD have increased in the HAART era.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146733     DOI: 10.1111/j.1468-1293.2009.00807.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  18 in total

1.  [Achalasia in a patient with HIV/HCV coinfection: detection of HCV in the esophageal tissue].

Authors:  H R Gockel; I Gockel; D G Drescher; H Müller; A Schad; J M Kittner; H Rossmann; H Lang
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

2.  Differences in antigen-specific CD4+ responses to opportunistic infections in HIV infection.

Authors:  Katrina M Pollock; Damien J Montamat-Sicotte; Graham S Cooke; Moses S Kapembwa; Onn M Kon; Lisa Grass; Robert D Sampson; Graham P Taylor; Ajit Lalvani
Journal:  Immun Inflamm Dis       Date:  2015-04-29

3.  Prevalence, Predictors, and Outcomes of Esophageal Candidiasis in Cirrhosis: An Observational Study With Systematic Review and Meta-Analysis (CANDID-VIEW).

Authors:  Nipun Verma; Saurabh Mishra; Shreya Singh; Arka De; Madhumita Premkumar; Sunil Taneja; Ajay Duseja; Virendra Singh
Journal:  J Clin Exp Hepatol       Date:  2021-03-21

4.  Human immunodeficiency virus-associated gastrointestinal disease: common endoscopic biopsy diagnoses.

Authors:  Feriyl Bhaijee; Charu Subramony; Shou-Jiang Tang; Dominique J Pepper
Journal:  Patholog Res Int       Date:  2011-04-26

5.  Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients.

Authors:  Yuta Takahashi; Naoyoshi Nagata; Takuro Shimbo; Takeshi Nishijima; Koji Watanabe; Tomonori Aoki; Katsunori Sekine; Hidetaka Okubo; Kazuhiro Watanabe; Toshiyuki Sakurai; Chizu Yokoi; Masao Kobayakawa; Hirohisa Yazaki; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Sohtaro Mine; Toru Igari; Yuko Takahashi; Akio Mimori; Shinichi Oka; Junichi Akiyama; Naomi Uemura
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  HIV-Helicobacter pylori Co-Infection: Antibiotic Resistance, Prevalence, and Risk Factors.

Authors:  Marcel Nkuize; Stéphane De Wit; Vinciane Muls; Marc Delforge; Véronique Y Miendje Deyi; Guy B Cadière; Michel Buset
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

7.  Retracted: Increased risk of stomach and esophageal malignancies in people with AIDS.

Authors:  E Christina Persson; Meredith S Shiels; Sanford M Dawsey; Kishor Bhatia; Lesley A Anderson; Eric A Engels
Journal:  Gastroenterology       Date:  2012-07-14       Impact factor: 22.682

8.  Gastrointestinal symptoms in HIV-positive kidney transplant candidates and recipients from an HIV-positive donor.

Authors:  C J Martin; F J Veldman; D Labadarios; Z Ebrahim; E Muller; S M Kassier
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

Review 9.  Polypharmacy in the HIV-infected older adult population.

Authors:  Lauren J Gleason; Amneris E Luque; Krupa Shah
Journal:  Clin Interv Aging       Date:  2013-06-21       Impact factor: 4.458

10.  Factors associated with esophageal candidiasis and its endoscopic severity in the era of antiretroviral therapy.

Authors:  So Nishimura; Naoyoshi Nagata; Takuro Shimbo; Naoki Asayama; Junichi Akiyama; Norio Ohmagari; Hirohisa Yazaki; Shinichi Oka; Naomi Uemura
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.